determine which companies have received violations for mass compounding of drugs.
Medicare pays for compounded medications mostly under what is called Part B, which covers drugs that patients cannot administer themselves, such as spinal injections and intravenous cancer drugs. These medications are vital and often life-sustaining and should be covered in full, said David Ball, a spokesman for the International Academy of Compounding Pharmacists.
Also weighing in on compounding on Monday, the Senate Committee on Health, Education, Labor, and Pensions asked all 50 state boards of pharmacy - which, rather than federal regulators, oversee compounding pharmacies - for information on actions you have taken to address this meningitis outbreak.
Specifically, the committee asked the boards whether they had reported problems with drugs from New England Compounding Center, the company that produced the tainted steroids, to the FDA, and whether they require compounding pharmacies to report whether they produce large volumes of drugs.
Although traditional pharmacy compounding is small-scale, producing one prescription for one specific patient at a time, the company that produced the tainted steroids in the meningitis outbreak manufactured thousands of doses for hundreds of patients at once, documents show.
OUT OF BUSINESS
The suspicion that Medicare's payment policy encourages large-scale compounding has arisen in part because in the single instance when Medicare denied payment for an entire class of compounded drugs - respiratory medications used in special inhalers called nebulizers - the decision drove compounders out of that business.
At the time, Medicare said that because compounded drugs are not tested for safety and effectiveness, they have the potential of putting a patient at increased risk of injury, illness, or death.
The nebulizer-drugs decision came in 2007, after patient advocates led by Allergy & Asthma Network Mothers of Asthmatics argued to Medicare that the compounded nebulizer drugs had contamination and potency problems, said Sandra Fusco Walker, who led that effort.
That coverage decision is absolutely relevant to the question of Medicare's support for compounding pharmacies, Blumenthal said, because it reflects an awareness of this issue. Whether that should be a precedent for denying coverage of all such (compounded) drugs